Abstract
Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Bryostatins
-
Disease Progression
-
Enzyme Activation
-
Female
-
Humans
-
Infusions, Intravenous
-
Lactones / administration & dosage*
-
Lactones / adverse effects
-
Macrolides
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / pathology
-
Neoplasms, Glandular and Epithelial / drug therapy*
-
Neoplasms, Glandular and Epithelial / pathology
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / pathology
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Bryostatins
-
Lactones
-
Macrolides
-
bryostatin 1